IP Library Granted Patent US 9,381,186
Granted Patent B2
US 9,381,186 · App. 14/829,507 · Granted Jul 5, 2016

Substituted chroman derivatives, medicaments and use in therapy

Inventors: Andrew Heaton (Alexandria, AU); Alan James Husband (Pyrmont, AU)
Assignee: MEI PHARMA, INC.
A61K31/353A23L1/30A23L2/52A61K45/06C07D311/38C07D311/58A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,381,186
App. No.
14/829,507
Granted
Jul 5, 2016
Kind
B2
Abstract

Novel substituted chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

Claims (14)

1. A composition comprising a compound of formula (I-b):

or a pharmaceutically acceptable salt thereof wherein:

R 1 is C 1-6 alkyl;

the drawing “—” and R 2 together represent a double bond or the drawing “—” represents a single bond and R 2 is hydrogen or hydroxy,

R 3 , R 4 and R 5 are independently hydrogen, hydroxy, C 1-6 alkoxy, or C 1-6 alkyl;

R 6 is hydrogen;

R 7 is C 1-6 alkoxy; and

R 8 and R 9 are independently hydrogen, hydroxy, halo, C 1-6 alkoxy, or C 1-6 alkyl;

wherein said composition is optionally in association with one or more pharmaceutical carriers, excipients, auxiliaries and/or diluents.

2. The composition of claim 1 , wherein R 1 is methyl.

3. The composition of claim 1 , wherein R 7 is methoxy.

4. The composition of claim 1 , further comprising an anti-cancer agent.

5. The composition of claim 4 , wherein the anti-cancer agent is cisplatin, dehydroequol, or paclitaxel.

6. The composition of claim 5 , wherein the anti-cancer agent is dehydroequol.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2015
From: HEATON, ANDREW; HUSBAND, ALAN
To: NOVOGEN RESEARCH PTY LTD
Reel/Frame 036380/0157 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2015
From: NOVOGEN LIMITED
To: MARSHALL EDWARDS, INC.
Reel/Frame 036380/0224 →
CHANGE OF NAME Recorded Aug 20, 2015
From: MARSHALL EDWARDS, INC.
To: MEI PHARMA, INC.
Reel/Frame 036380/0308 →
Priority Claims (1)
WO PCT/AU2004/001619 · Nov 19, 2004 · international
Continuity (7)
Division 14186940 · Feb 21, 2014
Continuation 13293947 · Nov 10, 2011
Continuation 12551277 · Aug 31, 2009
Division 11230726 · Sep 21, 2005
Provisional Application 60611300 · Sep 21, 2004
Provisional Application 60676934 · May 3, 2005
Related Publication 20150352074A1 · Dec 10, 2015